CWA Asset Management Group Reduces Bristol Myers Squibb Stake

Firm sells 35,291 shares of biopharmaceutical company in Q4 2025

Mar. 21, 2026 at 9:04am

Got story updates? Submit your updates here. ›

CWA Asset Management Group LLC reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 23.5% during the fourth quarter of 2025, according to a recent SEC filing. The firm sold 35,291 shares, leaving it with 115,068 shares worth $6.2 million at the end of the reporting period.

Why it matters

Bristol Myers Squibb is a major biopharmaceutical company, and changes in institutional ownership of its stock can provide insights into investor sentiment and market trends around the company's performance and prospects.

The details

CWA Asset Management Group, an investment management firm, sold 35,291 shares of Bristol Myers Squibb in Q4 2025, reducing its total position to 115,068 shares. The firm cited portfolio rebalancing and changes in its investment strategy as the reasons for the sale.

  • CWA Asset Management Group filed its Q4 2025 holdings disclosure in March 2026.

The players

CWA Asset Management Group LLC

An investment management firm that reduced its stake in Bristol Myers Squibb in Q4 2025.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in CWA Asset Management Group's Bristol Myers Squibb position reflects broader portfolio adjustments by the firm, but does not necessarily indicate a broader shift in investor sentiment around the biopharmaceutical company's outlook.